Drug Database
FL

fluvoxamine (Favoxil CR / Favoxile CR / fluvoxamine CR)

✓ Approved

Astellas Pharma · SLC6A4 · Small Molecule

What is fluvoxamine?

fluvoxamine is a small molecule developed by Astellas Pharma. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesFavoxil CR, Favoxile CR, fluvoxamine CR
CompanyAstellas Pharma
Drug ClassSmall Molecule
Molecular TargetSLC6A4
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Astellas Pharma

Mechanism of Action

Molecular Targets

fluvoxamine acts on 1 molecular target:

SLC6A4solute carrier family 6 member 4 (5HTT, 5-HTT)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

fluvoxamine is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersObsessive-compulsive disorder✓ Approved
Psychiatric disordersSocial anxiety disorder✓ Approved

Related Research Articles

PubMedInternational journal of endocrinology and metabolism2026-09-20

Comparative Incidence of Urinary Tract Infections in Diabetic Women Treated with Dapagliflozin Versus Empagliflozin: A Double-Blind Randomized Clinical Trial.

Kazem-Nadi Sara S, Keshtkari Sara S, Labbani-Motlagh Zohre Z, Mousavi Vahid V

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including dapagliflozin and empagliflozin, are widely used for glycemic control in type 2 diabetes but may affect the risk of urinary tract infection (UTI). This study compared the incidence of UTIs among women with diabetes treated with dapagliflozin versus empagliflozin. In this randomized, double-blind clinical trial, 149 diabetic women aged ≥ 18 years were assigned to receive dapagliflozin 5 mg (n = 79) or empagliflozin 10 mg (n = 70) daily for three months. Fasting blood sugar (FBS), glycated hemoglobin (HbA1c), and serum creatinine (Cr) were measured at baseline and after treatment. Urinalysis and urine culture were used to confirm UTIs. Data were analyzed using SPSS version 28.0, with P < 0.05 considered statistically significant. The mean age was 62.7 ± 9.7 years, with no baseline differences between groups. UTIs occurred in 12 patients overall: 2 (2.5%) in the dapagliflozin group and 10 (14.3%) in the empagliflozin group (OR = 0.16; 95% CI, 0.03 - 0.74; P = 0.009). No significant intergroup differences were observed in FBS, HbA1c, or Cr levels. Empagliflozin was associated with a higher short-term incidence of UTIs than dapagliflozin, despite similar metabolic outcomes. Monitoring for UTIs is recommended when prescribing SGLT2 inhibitors, particularly empagliflozin. Trial Registration: This trial is registered with the Iranian Registry of Clinical Trials (IRCT20250129064554N1).

PMID 42763716
Read full article →
PubMedRespiratory research2026-09-20

Prophylactic cranial irradiation versus active MRI surveillance for limited-stage small-cell lung cancer achieving response after chemoradiotherapy: a protocol for a randomized, controlled, multicenter, phase III trial.

Wei Zhonghui Z, Chen Yu Y, Yu Jinming J, Meng Xiangjiao X

Prophylactic cranial irradiation (PCI) is the standard preventive strategy for limited-stage small-cell lung cancer (LS-SCLC). However, the evidence supporting this strategy is largely based on the pre-MRI era. With the advancement of modern MRI and treatment techniques, the survival benefit of PCI remains unclear, particularly given the potential for neurocognitive toxicity to impair quality of life. This study aims to re-evaluate the value of PCI in contemporary LS-SCLC patients and investigate whether active MRI surveillance is non-inferior to PCI regarding overall survival (OS). This is a prospective, randomized, multicenter, phase III trial, enrolling patients with LS-SCLC who achieve complete response (CR) or partial response (PR) after platinum-based chemoradiotherapy. Participants will be randomly assigned (1:1) to receive either PCI or active MRI surveillance. The primary endpoint is OS. Secondary endpoints include 1- and 3-year OS rates, progression-free survival (PFS), brain metastasis rate, and neurocognitive function. Exploratory analyses will integrate clinical characteristics with the longitudinal kinetics of tumor biomarkers in collected peripheral blood to identify patient subgroups who are more likely to benefit from PCI. This study will re-evaluate the role of PCI in the MRI era for LS-SCLC. If active MRI surveillance proves non-inferior, it may provide evidence supporting a less intensive management approach that could potentially reduce treatment-related neurotoxicity and preserve quality of life. Furthermore, our trial aims to identify patient subgroups that derive a clinical benefit from PCI, and leverage serial biomarker dynamics to guide personalized clinical management for LS-SCLC patients. This trial is registered at ClinicalTrials.gov (NCT04829708).

PMID 42763407
Read full article →
PubMedCognitive neurodynamics2026-09-20

Shunting energy flow and current in a neural circuit.

Li Chaoran C, Chen Jiangxing J, Zhu Zhigang Z, Guo Yitong Y

Neural circuits serve as the fundamental tool for exploring the working mechanism of neurons, with the core being the firing activity mediated by ion channels. However, previous studies have shown a lack of sufficient exploration of the role of ion channels in neuronal electrical activities and their regulatory mechanisms. Ion channels not only serve as the basis for generating, conducting action potentials, and executing synaptic transmission, but also directly affect the processing and transmission of neural signals. To deeply analyze the precise influence of ion channels on neuronal firings, this study constructed a neural circuit model. Magnetic control memristors were introduced in the ion channel branch to enhance the effect of ion channels. At the same time, a capacitor C 2 was connected in parallel with the magnetic control memristor to achieve the shunting effect of the ion channel current. Additionally, by connecting a nonlinear resistor NR in series with the voltage source, we effectively broadened the stimulation frequency band and enriched the frequency response characteristics of neurons. Numerical simulation results show that this model can induce bifurcation phenomena between chaotic and periodic firings in the neuronal system by directly adjusting the parameters of ion channels. Its dynamic behavior exhibits significant dependence on the range of parameter adjustment. In terms of noise influence, it was found that the system can achieve coherent resonance (CR) at a lower noise intensity. Furthermore, we designed an adaptive energy control scheme, enabling neurons to spontaneously regulate the parameter λ of the shunt device according to their internal energy state, thereby achieving precise control of neuronal firing patterns. The results of this study provide a new perspective and theoretical basis for understanding and manipulating the role of ion channels in the signal processing of neurons.

PMID 42763483
Read full article →
PubMedEuropean archives of psychiatry and clinical neuroscience2026-09-19

Adverse event reporting patterns of selective serotonin reuptake inhibitors (SSRIs): disproportionality analysis using the European spontaneous reporting system.

Laino Ludovica Vittoria LV, Mascolo Annamaria A, Di Napoli Raffaella R, di Mauro Gabriella G et al.

We analysed adverse event reporting patterns associated with SSRIs using data from the European pharmacovigilance database, EudraVigilance. A descriptive analysis of individual case safety reports (ICSRs) was conducted between January 2020, 1st and December 2024, 31st. Disproportionality analysis were conducted for the two most frequently reported system organ classes (SOCs) and the three most frequently reported preferred terms (PTs). During the study period, 21,665 ICSRs reporting at least one SSRI as suspected drug were retrieved. A total of 78,132 adverse events were identified, and sertraline (N = 26,161; 33.5%) was the most reported SSRI. Most events were not serious, and the most reported criterion was Other Medically Important Condition (N = 19,603; 25.1%). The most frequent outcome was "Unknown" (N = 27,555). In the disproportionality analysis, for the SOC "Psychiatric Disorders", escitalopram and fluvoxamine showed a higher disproportionate reporting (ROR 1.08; 95% CI 1.03-1.13; ROR 1.15; 95% CI 1.01-1.31, respectively). For the SOC "Nervous System Disorders", paroxetine showed a higher disproportionate reporting (ROR 1.10; 95% CI 1.04-1.16). Headache higher disproportionate reporting with sertraline (ROR 1.17; 95% CI 1.04-1.30), while dizziness with escitalopram (ROR 1.42; 95% CI 1.25-1.61), and somnolence with fluvoxamine and paroxetine (ROR 1.86; 95% CI 1.27-2.72; ROR 1.58; 95% CI 1.33-1.89, respectively). SSRIs showed homogeneous adverse event reporting patterns, with relatively few differences in disproportional reporting between individual drugs. These results reinforce the importance of continuous pharmacovigilance monitoring.

PMID 42762244
Read full article →
PubMedBlood neoplasia2026-09-19

Tamibarotene with venetoclax and azacitidine in RARA+ acute myeloid leukemia: results from the SY-1425-202 study.

Cluzeau Thomas T, Borate Uma U, McMahon Christine C, Fenaux Pierre P et al.

RARA overexpression defines a molecularly distinct subset of acute myeloid leukemia (AML). Tamibarotene, an oral selective RARA agonist, synergizes with azacitidine (AZA) but its addition to venetoclax (VEN) with AZA has not been assessed. SY-1425-202 was a multicenter, open-label, randomized study evaluating tamibarotene combined to VEN/AZA (TAMI/VEN/AZA) vs VEN/AZA alone in newly diagnosed RARA-positive, unfit AML. Part 1 assessed the safety of TAMI/VEN/AZA, part 2 randomized participants to TAMI/VEN/AZA vs VEN/AZA, and part 3 explored salvage therapy with TAMI/VEN/AZA after VEN/AZA failure in part 2. TAMI 6 mg twice daily was administered. Randomization occurred after confirmation of RARA positivity by cycle 1, day 8. The primary end point was complete remission (CR) + CR with incomplete hematologic recovery (CRi) in part 2 and part 3, and safety in part 1. In part 1 (n=10), overall response rate (ORR) was 77.8% (5 CR, 2 CRi). In part 2 (n=51), CR/CRi was 60.0% for TAMI/VEN/AZA and 69.2% for VEN/AZA. Median CR/CRi duration was 293 vs 253 days. ORR was 80.0% vs 73.1%, respectively. In part 3, 2 of 5 patients responded (CR, morphologically leukemia-free state). Grade ≥3 treatment-emergent adverse event occurred in 76% of patients. Deaths were attributed mainly to disease progression or known complications of therapy; none were attributed to TAMI. The study met prespecified futility criteria and was discontinued early. The addition of TAMI to VEN/AZA was tolerable but did not improve efficacy over VEN/AZA. These results did not demonstrate clinical benefit of TAMI in the frontline unfit RARA-positive AML setting receiving VEN/AZA. This trial was registered at www.clinicaltrials.gov as #NCT04905407.

PMID 42761251
Read full article →
PubMedEnvironmental monitoring and assessment2026-09-19

Environmental assessment of the Ariyankuppam River, India: chromium and lead accumulation in Mugil cephalus and Azolla pinnata-mediated toxicity mitigation in Labeo rohita.

Manda Pushpa Latha PL, Reddy Kadimisetty Goutham KG, Saravanabhavan P P, Sheu Joen-Rong JR et al.

Heavy metals are persistent environmental pollutants that pose long-term risks to aquatic ecosystems and public health because of their non-biodegradable nature. This study was carried out under two complementary components, namely, an environmental assessment of the Ariyankuppam River, Puducherry, India and a controlled laboratory exposure experiment. Water, sediment, and Mugil cephalus samples were collected to assess the concentrations of heavy metals via inductively coupled plasma mass spectrometry (ICP-MS) in the field investigation. The major toxic metal found in water samples was chromium (Cr) with concentration of 0.058 ± 0.003 mg L⁻1 and in sediments (15.616 ± 6.672 mg kg⁻1), while lead (Pb) was consistently detected in all environmental matrices, indicating contamination and accumulation in fish tissues. Geochemical analyses using XRD, EDX, and XPS were used to identify crystalline and mineral phases associated with Cr and Pb in the sediment matrix. laboratory study, Labeo rohita were exposed to sublethal concentrations of Cr (5 mg L⁻1) and Pb (11 mg L⁻1) for 96 h. Heavy metal exposure significantly increased catalase (CAT) activity in gill tissues and decreased CAT activity in muscle tissues (p < 0.05), indicating tissue-specific oxidative stress responses. Alterations in protein band patterns were found by SDS-PAGE, while histopathological examination demonstrated marked damage to the gill, liver, and muscle tissues. Treatment with Azolla pinnata restored CAT activity toward control levels, reduced protein band alterations, and alleviated histopathological damage. Overall, the findings demonstrate the acute toxicity of Cr and Pb and highlight the potential of A. pinnata to mitigate heavy metal-induced toxicity under controlled laboratory conditions. Further long-term field studies are needed to evaluate its practical application in freshwater ecosystems.

PMID 42762356
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about fluvoxamine